Adicet Bio Inc. has obtained FDA clearance of its IND application to evaluate ADI-270, an armored allogeneic λδ CAR T-cell therapy candidate targeting CD70-positive cancers, for the treatment of relapsed or refractory renal cell carcinoma (RCC).
Immutep Ltd. has signed a license agreement with Cardiff University granting the company exclusive rights to develop and commercialize anti-LAG-3 small molecules.
Top-line phase III data from G1 Therapeutics Inc.’s pivotal Preserve 2 study of Cosela (trilaciclib) in treating metastatic triple-negative breast cancer missed its primary endpoint of overall survival, submerging the stock on June 24.
The BioWorld Biopharmaceutical Index (BBI) saw an 8.15% increase at the close of May, outperforming the Dow Jones Industrial Average, which rose by 2.64%, and the Nasdaq Biotechnology Index, which was up by 0.7%. The BBI previously showed a strong performance in Q1, followed by a dip for all three indices in April, before all rebounded in May.
Haisco Pharmaceutical Group Co. Ltd. has identified molecular glue degraders targeting protein cereblon (CRBN) acting as eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) degradation inducers reported to be useful for the treatment of cancer.
SSO-110, also known as DOTA-JR11 or satoreotide tetraxetran, is a somatostatin SST2 receptor (SSTR2) antagonist that targets a higher number of binding sites and stays longer in SSTR2-positive tumors compared to SST2 receptor agonists. It is currently in clinical development as [177Lu]Lu-SSO-110 for small-cell lung cancer (SCLC). Ariceum Therapeutics GmbH has revealed preclinical data on [177Lu]Lu-SSO-110 as well as another SSO-110-based radiopharmaceutical, [225Ac]Ac-SSO-110, which yielded better results than DOTA-TATE-conjugated isotopes.
Medigene AG has selected its lead candidate for MDG-2021, a T-cell receptor engineered T-cell (TCR-T) therapy targeting KRAS G12D with human leukocyte antigen (HLA)-A*11 being developed in combination with the company’s PD1-41BB costimulatory switch protein (CSP) technology.
Bispecific CD20×CD3 T-cell engagers have shown efficacy in hematological malignancies; however, associated toxicities such as cytokine release syndrome and immune effector-associated neurotoxicity syndrome limit their use.
Ionctura SA closed a €80 million (US$86 million) series B round as it prepares to accelerate development of lead asset roginolisib in the treatment of uveal melanoma. That follows publication of phase Ib data showing roginolisib, an orally available allosteric modulator of the delta isoform of PI3K (phosphatidylinositol-4,5-bisphosphate kinase), is distinguished from other drugs in this class, in being well-tolerated over long periods, with patients having been treated for up to 38 months.
RSS
